{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T04:18:45Z","timestamp":1743394725135,"version":"3.40.3"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100023674","name":"Deanship of Scientific Research, King Khalid University","doi-asserted-by":"publisher","award":["RGP.2\/315\/44","RGP.2\/315\/44","RGP.2\/315\/44","RGP.2\/315\/44"],"award-info":[{"award-number":["RGP.2\/315\/44","RGP.2\/315\/44","RGP.2\/315\/44","RGP.2\/315\/44"]}],"id":[{"id":"10.13039\/501100023674","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-025-02656-x","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T06:41:28Z","timestamp":1741848088000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dual targeting of CXC chemokine receptor 4 and multidrug resistance protein 1 by ZIN056 effectively combat daunorubicin resistance in acute myeloid leukemia cells"],"prefix":"10.1007","volume":"42","author":[{"given":"Mohammad","family":"Abohassan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mesfer Mohammad","family":"Al Shahrani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah Khaled","family":"AlOuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prasanna","family":"Rajagopalan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,13]]},"reference":[{"issue":"8","key":"2656_CR1","first-page":"e3198","volume":"10","author":"A Saif","year":"2018","unstructured":"Saif A, et al. Acute myeloid leukemia: is that all there is? Cureus. 2018;10(8):e3198.","journal-title":"Cureus"},{"issue":"10","key":"2656_CR2","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.3324\/haematol.2020.269134","volume":"106","author":"SR McCurdy","year":"2021","unstructured":"McCurdy SR, Luger SM. Dose intensity for induction in acute myeloid leukemia: what, when, and for whom? Haematologica. 2021;106(10):2544\u201354.","journal-title":"Haematologica"},{"issue":"11","key":"2656_CR3","doi-asserted-by":"crossref","first-page":"5789","DOI":"10.3390\/ijms22115789","volume":"22","author":"MK Song","year":"2021","unstructured":"Song MK, Park BB, Uhm JE. Targeted therapeutic approach based on understanding of aberrant molecular pathways leading to leukemic proliferation in patients with acute myeloid leukemia. Int J Mol Sci. 2021;22(11):5789.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"2656_CR4","doi-asserted-by":"crossref","first-page":"754","DOI":"10.3390\/cancers16040754","volume":"16","author":"I Elmakaty","year":"2024","unstructured":"Elmakaty I, et al. The contemporary role of hematopoietic stem cell transplantation in the management of chronic myeloid leukemia: is it the same in all settings? Cancers (Basel). 2024;16(4):754.","journal-title":"Cancers (Basel)"},{"key":"2656_CR5","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.2147\/CMAR.S234883","volume":"12","author":"Z Yazdani","year":"2020","unstructured":"Yazdani Z, et al. Significance of CXCL12\/CXCR4 ligand\/receptor axis in various aspects of acute myeloid leukemia. Cancer Manag Res. 2020;12:2155\u201365.","journal-title":"Cancer Manag Res"},{"issue":"2","key":"2656_CR6","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3904\/kjim.2016.244","volume":"32","author":"BS Cho","year":"2017","unstructured":"Cho BS, Kim HJ, Konopleva M. Targeting the CXCL12\/CXCR4 axis in acute myeloid leukemia: from bench to bedside. Korean J Intern Med. 2017;32(2):248\u201357.","journal-title":"Korean J Intern Med"},{"issue":"8","key":"2656_CR7","doi-asserted-by":"crossref","first-page":"26414","DOI":"10.1002\/pbc.26414","volume":"64","author":"TM Cooper","year":"2017","unstructured":"Cooper TM, et al. A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: a pediatric oncology experimental therapeutics investigators\u2019 consortium study (POE 10-03). Pediatr Blood Cancer. 2017;64(8):26414.","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"2656_CR8","doi-asserted-by":"crossref","first-page":"5567","DOI":"10.3892\/ijo.2023.5567","volume":"63","author":"Y Tian","year":"2023","unstructured":"Tian Y, et al. Mechanism of multidrug resistance to chemotherapy mediated by P-glycoprotein (Review). Int J Oncol. 2023;63(5):5567.","journal-title":"Int J Oncol"},{"issue":"20","key":"2656_CR9","doi-asserted-by":"crossref","first-page":"5062","DOI":"10.1182\/bloodadvances.2020001576","volume":"4","author":"E Morrish","year":"2020","unstructured":"Morrish E, et al. Clinical MDR1 inhibitors enhance Smac-mimetic bioavailability to kill murine LSCs and improve survival in AML models. Blood Adv. 2020;4(20):5062\u201377.","journal-title":"Blood Adv"},{"issue":"12","key":"2656_CR10","doi-asserted-by":"crossref","first-page":"e1499388","DOI":"10.1080\/2162402X.2018.1499388","volume":"7","author":"M Bossennec","year":"2018","unstructured":"Bossennec M, et al. MDR1 in immunity: friend or foe? Oncoimmunology. 2018;7(12):e1499388.","journal-title":"Oncoimmunology"},{"issue":"6","key":"2656_CR11","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s00280-019-03825-2","volume":"83","author":"S Adige","year":"2019","unstructured":"Adige S, et al. Equipotent doses of daunorubicin and idarubicin for AML: a meta-analysis of clinical trials versus in vitro estimation. Cancer Chemother Pharmacol. 2019;83(6):1105\u201312.","journal-title":"Cancer Chemother Pharmacol"},{"key":"2656_CR12","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.2147\/OTT.S191621","volume":"12","author":"J Zhang","year":"2019","unstructured":"Zhang J, Gu Y, Chen B. Mechanisms of drug resistance in acute myeloid leukemia. Onco Targets Ther. 2019;12:1937\u201345.","journal-title":"Onco Targets Ther"},{"issue":"7","key":"2656_CR13","doi-asserted-by":"crossref","first-page":"861","DOI":"10.2174\/138945006777709593","volume":"7","author":"S Nobili","year":"2006","unstructured":"Nobili S, et al. Pharmacological strategies for overcoming multidrug resistance. Curr Drug Targets. 2006;7(7):861\u201379.","journal-title":"Curr Drug Targets"},{"issue":"5","key":"2656_CR14","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/leu.2011.360","volume":"26","author":"E Weisberg","year":"2012","unstructured":"Weisberg E, et al. Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib. Leukemia. 2012;26(5):985\u201390.","journal-title":"Leukemia"},{"issue":"12","key":"2656_CR15","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1158\/1535-7163.MCT-06-0228","volume":"5","author":"Z Zeng","year":"2006","unstructured":"Zeng Z, et al. Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias. Mol Cancer Ther. 2006;5(12):3113\u201321.","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"2656_CR16","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1124\/mol.108.053389","volume":"75","author":"I Kalatskaya","year":"2009","unstructured":"Kalatskaya I, et al. AMD3100 is a CXCR7 ligand with allosteric agonist properties. Mol Pharmacol. 2009;75(5):1240\u20137.","journal-title":"Mol Pharmacol"},{"issue":"7","key":"2656_CR17","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1182\/blood-2006-07-035857","volume":"109","author":"Y Alsayed","year":"2007","unstructured":"Alsayed Y, et al. Mechanisms of regulation of CXCR4\/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood. 2007;109(7):2708\u201317.","journal-title":"Blood"},{"issue":"4","key":"2656_CR18","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.tiv.2008.01.004","volume":"22","author":"F Klamt","year":"2008","unstructured":"Klamt F, et al. Inhibition of MDR1 expression by retinol treatment increases sensitivity to etoposide (VP16) in human neoplasic cell line. Toxicol In Vitro. 2008;22(4):873\u20138.","journal-title":"Toxicol In Vitro"},{"key":"2656_CR19","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1186\/1756-0500-5-367","volume":"5","author":"AW Sousa da Silva","year":"2012","unstructured":"Sousa da Silva AW, Vranken WF. ACPYPE - AnteChamber PYthon parser interfacE. BMC Res Notes. 2012;5:367.","journal-title":"BMC Res Notes"},{"issue":"10","key":"2656_CR20","doi-asserted-by":"crossref","first-page":"6281","DOI":"10.1021\/acs.jctc.1c00645","volume":"17","author":"MS Vald\u00e9s-Tresanco","year":"2021","unstructured":"Vald\u00e9s-Tresanco MS, et al. gmx_MMPBSA: a new tool to perform end-state free energy calculations with GROMACS. J Chem Theory Comput. 2021;17(10):6281\u201391.","journal-title":"J Chem Theory Comput"},{"issue":"3","key":"2656_CR21","doi-asserted-by":"crossref","first-page":"217","DOI":"10.32604\/or.2022.03570","volume":"29","author":"HM Otifi","year":"2021","unstructured":"Otifi HM, et al. Computational docking and in vitro analysis identifies novel arylidene analogue FPMXY-14 against renal cancer cells by attenuating Akt. Oncol Res. 2021;29(3):217\u201327.","journal-title":"Oncol Res"},{"issue":"6007","key":"2656_CR22","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1126\/science.1194396","volume":"330","author":"B Wu","year":"2010","unstructured":"Wu B, et al. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science. 2010;330(6007):1066\u201371.","journal-title":"Science"},{"key":"2656_CR23","first-page":"205","volume":"6","author":"TL Lin","year":"2012","unstructured":"Lin TL, Levy MY. Acute myeloid leukemia: focus on novel therapeutic strategies. Clin Med Insights Oncol. 2012;6:205\u201317.","journal-title":"Clin Med Insights Oncol"},{"issue":"1","key":"2656_CR24","doi-asserted-by":"crossref","first-page":"563","DOI":"10.3390\/ijms24010563","volume":"24","author":"KA Skelding","year":"2022","unstructured":"Skelding KA, et al. Bone marrow microenvironment as a source of new drug targets for the treatment of acute myeloid leukaemia. Int J Mol Sci. 2022;24(1):563.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2656_CR25","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1021\/acsmedchemlett.8b00441","volume":"10","author":"BM Katzman","year":"2019","unstructured":"Katzman BM, et al. Tetrahydroisoquinoline CXCR4 antagonists adopt a hybrid binding mode within the peptide subpocket of the CXCR4 receptor. ACS Med Chem Lett. 2019;10(1):67\u201373.","journal-title":"ACS Med Chem Lett"},{"key":"2656_CR26","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.3389\/fonc.2020.01672","volume":"10","author":"D Cancilla","year":"2020","unstructured":"Cancilla D, Rettig MP, DiPersio JF. Targeting CXCR4 in AML and ALL. Front Oncol. 2020;10:1672.","journal-title":"Front Oncol"},{"issue":"24","key":"2656_CR27","doi-asserted-by":"crossref","first-page":"6215","DOI":"10.1182\/blood-2008-05-158311","volume":"113","author":"Z Zeng","year":"2009","unstructured":"Zeng Z, et al. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood. 2009;113(24):6215\u201324.","journal-title":"Blood"},{"issue":"2","key":"2656_CR28","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/j.1460-2075.1982.tb01145.x","volume":"1","author":"M Staehelin","year":"1982","unstructured":"Staehelin M, Simons P. Rapid and reversible disappearance of beta-adrenergic cell surface receptors. Embo J. 1982;1(2):187\u201390.","journal-title":"Embo J"},{"issue":"7","key":"2656_CR29","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1038\/sj.bjp.0702234","volume":"125","author":"SJ Mundell","year":"1998","unstructured":"Mundell SJ, Kelly E. The effect of inhibitors of receptor internalization on the desensitization and resensitization of three Gs-coupled receptor responses. Br J Pharmacol. 1998;125(7):1594\u2013600.","journal-title":"Br J Pharmacol"},{"issue":"30","key":"2656_CR30","doi-asserted-by":"crossref","first-page":"20991","DOI":"10.1074\/jbc.M114.560680","volume":"289","author":"Y Zhuo","year":"2014","unstructured":"Zhuo Y, et al. Identification of receptor binding-induced conformational changes in non-visual arrestins. J Biol Chem. 2014;289(30):20991\u20131002.","journal-title":"J Biol Chem"},{"issue":"9","key":"2656_CR31","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1093\/jnci\/djv222","volume":"107","author":"MM Gottesman","year":"2015","unstructured":"Gottesman MM, Pastan IH. The role of multidrug resistance efflux pumps in cancer: revisiting a JNCI publication exploring expression of the MDR1 (P-glycoprotein) gene. J Natl Cancer Inst. 2015;107(9):222.","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"2656_CR32","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.3390\/cancers15123145","volume":"15","author":"G Rodr\u00edguez-Mac\u00edas","year":"2023","unstructured":"Rodr\u00edguez-Mac\u00edas G, et al. Role of intracellular drug disposition in the response of acute myeloid leukemia to cytarabine and idarubicin induction chemotherapy. Cancers (Basel). 2023;15(12):3145.","journal-title":"Cancers (Basel)"},{"issue":"18","key":"2656_CR33","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1007\/s40265-018-1022-3","volume":"78","author":"HA Blair","year":"2018","unstructured":"Blair HA. Daunorubicin\/cytarabine liposome: a review in acute myeloid leukaemia. Drugs. 2018;78(18):1903\u201310.","journal-title":"Drugs"},{"issue":"12","key":"2656_CR34","first-page":"e33165","volume":"14","author":"EY Arwanih","year":"2022","unstructured":"Arwanih EY, et al. Resistance mechanism of acute myeloid leukemia cells against daunorubicin and cytarabine: a literature review. Cureus. 2022;14(12):e33165.","journal-title":"Cureus"},{"issue":"5","key":"2656_CR35","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/bjc.1995.180","volume":"71","author":"XF Hu","year":"1995","unstructured":"Hu XF, et al. Rapid up-regulation of mdr1 expression by anthracyclines in a classical multidrug-resistant cell line. Br J Cancer. 1995;71(5):931\u20136.","journal-title":"Br J Cancer"},{"key":"2656_CR36","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-230X-8-33","volume":"8","author":"TB Lee","year":"2008","unstructured":"Lee TB, et al. Epigenetic mechanisms involved in differential MDR1 mRNA expression between gastric and colon cancer cell lines and rationales for clinical chemotherapy. BMC Gastroenterol. 2008;8:33.","journal-title":"BMC Gastroenterol"},{"issue":"4","key":"2656_CR37","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1023\/A:1006416410198","volume":"18","author":"JL Grem","year":"2000","unstructured":"Grem JL. 5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development. Invest New Drugs. 2000;18(4):299\u2013313.","journal-title":"Invest New Drugs"},{"issue":"1","key":"2656_CR38","first-page":"66","volume":"34","author":"Y Li","year":"2014","unstructured":"Li Y, et al. Effect and mechanisms of TET on human gastric carcinoma cell line SGC7901 and SGC7901\/ADR. Zhongguo Zhong Xi Yi Jie He Za Zhi Chinese J Integr Traditional and West Med. 2014;34(1):66\u201370.","journal-title":"Zhongguo Zhong Xi Yi Jie He Za Zhi Chinese J Integr Traditional and West Med"},{"key":"2656_CR39","doi-asserted-by":"crossref","first-page":"12385","DOI":"10.2147\/CMAR.S274599","volume":"12","author":"WJ Huang","year":"2020","unstructured":"Huang WJ, et al. Multidrug resistance of gastric cancer: the mechanisms and chinese medicine reversal agents. Cancer Manag Res. 2020;12:12385\u201394.","journal-title":"Cancer Manag Res"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02656-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-02656-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02656-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T00:34:04Z","timestamp":1743381244000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-02656-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,13]]},"references-count":39,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["2656"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-02656-x","relation":{},"ISSN":["1559-131X"],"issn-type":[{"type":"electronic","value":"1559-131X"}],"subject":[],"published":{"date-parts":[[2025,3,13]]},"assertion":[{"value":"13 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there is no conflict of interest related to this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors give their consent to the journal for publication of this manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human and animal rights"}}],"article-number":"106"}}